肿瘤病人化疗、免疗及免疫化疗前后NK－IL－2－IFN－r系统变化

本文观察了４６例中晚期肿瘤病人化疗、免疗（抗瘤ｉＲＮＡ及Ｓ－ＴＦ）及免疫化疗前后ＮＫ－ＩＬ－２－ＩＦＮ－ｒ系统及ＷＢＣ等变化。结果发现：（１）肿瘤病人ＮＫ、ＩＬ－２及ＩＦＮ－ｒ活性均显著低于正常人；（２）化疗后除ＷＢＣ明显降低外，其它指标化疗前后均无明显变化；（３）免疫及免疫化疗后各免疫指标均较治疗前显著增加；（４）免化组各免疫指标及ＷＢＣ明显高于化疗组，其中ＩＬ－２及ＩＦＮ－ｒ活性还明显高于免疫组，但免疫组仅ＩＬ－２活性及ＷＢＣ明显高于化疗组。本研究结果表明，抗瘤ｉＲＮＡ及Ｓ－ＴＦ不仅可恢复肿瘤宿主的免疫力，而且与化疗联用，还可能降低化疗的毒副反应，协调肿瘤病人ＮＫ－ＩＬ－２－ＩＦＮ－ｒ系统的抗癌功能。

EFFECTS OF CHEMOTHERAPY,IMMUNOTHERAPY AND IMMUNOCHEMOTHERAPY ON NK-IL-2-IFN-R IN CANCER PATIENTS

Abstract Chemotherspy, immunotherapy and immunochemotherapy were tested for thire effects on NK-IL-2-IFN-r in 46 patients with advanced cancer. The results showed that (1) the NK, IL-2 andIFN-r activities in the cancer patients were significantly lower than those in controls;(2) both be- fore and after chemotherapy there were no apparently changes in the NK, IL-2 and IFN-r activityexcept for WBC; (3) the immune indexes were apparently increased after immunotherapy and immunochemotherapy as compared to those before, and (4) the IL-2 and IFN-r activity in immunochemotherapy group were significantly higher than chemotherapy and immunotherapy grouprespectively, but the NK activity in immunochemotherapy group was significantly than that only inchemotherapy group and the IL-2 activity and WBC in immunotherapy group were apparentlyhigher than those in chemotherapy group. It is concluded that the immune function in the host canbe restored by adiministrating iRNA and S-TF, and either the side effects of chemotherapy can bereduced or an synergistical immunoregulation of NK-IL-2-IFN-r aganist cancer can be enhanced inthe patients by combining chemotherapy with iRNA and S-TF.